Cutaneous leishmaniasis (CL) is caused by Leishmania infection of dermal macrophages and is associated with chronic inflammation of the skin. L. aethiopica infection displays two clinical manifestations, firstly ulcerative disease, correlated to a relatively low parasite load in the skin, and secondly non-ulcerative disease in which massive parasite infiltration of the dermis occurs in the absence of ulceration of epidermis. Skin ulceration is linked to a vigorous local inflammatory response within the skin towards infected macrophages. Fas ligand (FasL) and Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expressing cells are present in dermis in ulcerative CL and both death ligands cause apoptosis of keratinocytes in the context of Leishmania infection. In the present report we show a differential expression of FasL and TRAIL in ulcerative and non-ulcerative disease caused by L. aethiopica. In vitro experiments confirmed direct FasL- and TRAIL-induced killing of human keratinocytes in the context of Leishmania-induced inflammatory microenvironment. Systemic neutralisation of FasL and TRAIL reduced ulceration in a model of murine Leishmania infection with no effect on parasitic loads or dissemination. Interestingly, FasL neutralisation reduced neutrophil infiltration into the skin during established infection, suggesting an additional proinflammatory role of FasL in addition to direct keratinocyte killing in the context of parasite-induced skin inflammation. FasL signalling resulting in recruitment of activated neutrophils into dermis may lead to destruction of the basal membrane and thus allow direct FasL mediated killing of exposed keratinocytes in vivo. Based on our results we suggest that therapeutic inhibition of FasL and TRAIL could limit skin pathology during CL.
References
[1]
Akuffo H, Schurr E, Andersson G, Yamaneberhan T, Britton S (1987) Responsiveness in diffuse versus local cutaneous leishmaniasis is due to parasite differences. Scand J Immunol 26: 717–721. doi: 10.1111/j.1365-3083.1987.tb02308.x
[2]
Lemma A, Foster WA, Gemetchu T, Preston PM, Bryceson A, et al. (1969) Studies on leishmaniasis in Ethiopia. I. Preliminary investigations into the epidemiology of cutaneous leishmaniasis in the highlands. Ann Trop Med Parasitol 63: 455–472.
[3]
Bryceson AD (1970) Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 64: 380–393. doi: 10.1016/0035-9203(70)90174-4
[4]
Akuffo HO, Fehniger TE, Britton S (1988) Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression. J Immunol 141: 2461–2466.
[5]
Schurr E, Wunderlich F, Tadesse G (1987) Electron microscopical studies on cutaneous leishmaniasis in Ethiopia. II. Parasite and host cell differences between the localized and the diffuse form. Acta Trop 44: 395–407.
[6]
Akuffo H, Maasho K, Blostedt M, Hojeberg B, Britton S, et al. (1997) Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. J Infect Dis 175: 737–741. doi: 10.1093/infdis/175.3.737
[7]
Eidsmo L, Nylen S, Khamesipour A, Hedblad MA, Chiodi F, et al. (2005) The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am J Pathol 166: 1099–1108. doi: 10.1016/S0002-9440(10)62330-9
[8]
Eidsmo L, Fluur C, Rethi B, Eriksson Ygberg S, Ruffin N, et al. (2007) FasL and TRAIL induce epidermal apoptosis and skin ulceration upon exposure to Leishmania major. Am J Pathol 170: 227–239. doi: 10.2353/ajpath.2007.060068
[9]
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, et al. (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106: 761–771. doi: 10.1083/jcb.106.3.761
[10]
da Silva R, Sacks DL (1987) Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect Immun 55: 2802–2806.
[11]
Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, et al. (2000) A natural model of Leishmania major infection reveals a prolonged “silent” phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165: 969–977.
[12]
Kayagaki N, Yamaguchi N, Nagao F, Matsuo S, Maeda H, et al. (1997) Polymorphism of murine Fas ligand that affects the biological activity. PNAS 94: 3914–3919. doi: 10.1073/pnas.94.8.3914
[13]
Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, et al. (1999) Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 163: 1906–1913.
[14]
Mustafa T, Bjune TG, Jonsson R, Pando RH, Nilsen R (2001) Increased expression of fas ligand in human tuberculosis and leprosy lesions: a potential novel mechanism of immune evasion in mycobacterial infection. Scand J Immunol 54: 630–639. doi: 10.1046/j.1365-3083.2001.01020.x
[15]
Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, et al. (1998) Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 188: 1941–1953. doi: 10.1084/jem.188.10.1941
[16]
Mendez S, Gurunathan S, Kamhawi S, Belkaid Y, Moga MA, et al. (2001) The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J Immunol 166: 5122–5128.
[17]
Conceicao-Silva F, Hahne M, Schroter M, Louis J, Tschopp J (1998) The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol 28: 237–245. doi: 10.1002/(SICI)1521-4141(199801)28:01<237::AID-IMMU237>3.0.CO;2-O
[18]
Huang FP, Xu D, Esfandiari EO, Sands W, Wei XQ, et al. (1998) Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol 160: 4143–4147.
[19]
Chakour R, Guler R, Bugnon M, Allenbach C, Garcia I, et al. (2003) Both the Fas ligand and inducible nitric oxide synthase are needed for control of parasite replication within lesions in mice infected with Leishmania major whereas the contribution of tumor necrosis factor is minimal. Infect Immun 71: 5287–5295. doi: 10.1128/IAI.71.9.5287-5295.2003
[20]
Roths JB, Murphy ED, Eicher EM (1984) A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 159: 1–20. doi: 10.1084/jem.159.1.1
[21]
Chakour R, Allenbach C, Desgranges F, Charmoy M, Mauel J, et al. (2009) A new function of the Fas-FasL pathway in macrophage activation. J Leukoc Biol 86: 81–90. doi: 10.1189/jlb.1008590
[22]
Harms G, Zwingenberger K, Chehade AK, Talhari S, Racz P, et al. (1989) Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet 1: 1287–1292. doi: 10.1016/S0140-6736(89)92686-X
[23]
Bomfim G, Andrade BB, Santos S, Clarencio J, Barral-Netto M, et al. (2007) Cellular analysis of cutaneous leishmaniasis lymphadenopathy: insights into the early phases of human disease. Am J Trop Med Hyg 77: 854–859.
[24]
Bretana A, Avila JL, Lizardo G, Convit J, Rondon AJ (1983) Leishmania species: comparative ultrastructure of experimental nodules and diffuse human cutaneous lesions in American leishmaniases. Exp Parasitol 55: 377–385. doi: 10.1016/0014-4894(83)90035-8
[25]
Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, et al. (2009) IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol 182: 3039–3046. doi: 10.4049/jimmunol.0713598
[26]
Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, et al. (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321: 970–974. doi: 10.1126/science.1159194
[27]
Lima GM, Vallochi AL, Silva UR, Bevilacqua EM, Kiffer MM, et al. (1998) The role of polymorphonuclear leukocytes in the resistance to cutaneous Leishmaniasis. Immunol Lett 64: 145–151. doi: 10.1016/S0165-2478(98)00099-6
[28]
McFarlane E, Perez C, Charmoy M, Allenbach C, Carter KC, et al. (2008) Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun 76: 532–541. doi: 10.1128/IAI.01388-07
[29]
Guimaraes-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, et al. (2009) Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci U S A 106: 6748–6753. doi: 10.1073/pnas.0900226106
